Teva to acquire Cephalon for $6.8b

By HILLEL KOREN/GLOBES
May 2, 2011 15:25
1 minute read.

 
X

Dear Reader,
As you can imagine, more people are reading The Jerusalem Post than ever before. Nevertheless, traditional business models are no longer sustainable and high-quality publications, like ours, are being forced to look for new ways to keep going. Unlike many other news organizations, we have not put up a paywall. We want to keep our journalism open and accessible and be able to keep providing you with news and analyses from the frontlines of Israel, the Middle East and the Jewish World.

As one of our loyal readers, we ask you to be our partner.

For $5 a month you will receive access to the following:

  • A user experience almost completely free of ads
  • Access to our Premium Section
  • Content from the award-winning Jerusalem Report and our monthly magazine to learn Hebrew - Ivrit
  • A brand new ePaper featuring the daily newspaper as it appears in print in Israel

Help us grow and continue telling Israel’s story to the world.

Thank you,

Ronit Hasin-Hochman, CEO, Jerusalem Post Group
Yaakov Katz, Editor-in-Chief

UPGRADE YOUR JPOST EXPERIENCE FOR 5$ PER MONTH Show me later

Teva Pharmaceutical Industries Ltd. and biopharmaceutical company Cephalon on Monday announced that their boards of directors have unanimously approved an agreement by which Teva will acquire all of Cephalon's shares for $81.50 per share in cash, or a total value of $6.8 billion. This is a 5% premium on Cephalon's closing share price on Nasdaq on Friday.

The transaction is not conditional on financing and is expected to be completed in the third quarter of 2011.

Cephalon had revenue of $2.76 billion and net profit of $657 million in 2010 mainly from brand drugs treating cancer, central nervous system disorders and pain. The company has a market cap of $5.8 billion and based in Pennsylvania has 3,726 employees in its various facilities.

Teva's share price was up 2.25% on the TASE at NIS 159.20 after news of the acquisition was released this afternoon. The share price closed down 0.9% at $45.73 on Nasdaq yesterday, giving a market cap of $43 billion.

Teva says that the transaction serves its long term strategy of developing its branded and specialty pharmaceuticals business through diversification and expansion of the company’s product portfolio and pipeline. "The enlarged company will utilize its complementary commercial, R&D and operational capabilities and capture value by providing customers with a broad spectrum of specialty branded products," the announcement said..

Join Jerusalem Post Premium Plus now for just $5 and upgrade your experience with an ads-free website and exclusive content. Click here>>

Related Content

Breaking news
October 17, 2018
U.S. reliance on sanctions 'out of control,' Iran foreign minister says

By REUTERS